Trials Sponsors Conditions Drugs Pricing

Conditions

Immunomodulatory Drugs Killer-cell Immunoglobulin-like Receptors (KIRs)KIR Alleles (KIR AA)

Outcome Measures

Primary Outcomes (2)

the incidence of immune cause of recurrent implantation failure
3-6 months
the efficiency of immnomodulatory treatment on pregnancy rate in patients with KIR AA
3-6 months

Secondary Outcomes (1)

comparation between the pregnancy rates in KIR AA group and KIR Bx group
3-6 months

Study Arms (2)

KIR AA

EXPERIMENTAL

Patients from arm KIR AA received immunomodulatory treatment, and the pregnancy rate was calculated after this treatment, and compared to the one before the treatment

Diagnostic Test: Killer-cell immunoglobulin-like receptors (KIRs) testing

KIR BX

NO INTERVENTION

Patients from arm KIR BX did not receive immunomodulatory treatment, and the pregnancy rate was calculated and compared with the ones from arm KIRR AA- before and after immunomodulatory treatment

Interventions

Killer-cell immunoglobulin-like receptors (KIRs) testingDiagnostic test

patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.

Also known as: immunomodulatory treatment for KIR AA

KIR AA

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 49 Years

Sexfemale(Gender-based eligibility)

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

patients with an infertility diagnosis having an IVF procedure with at least two top-quality embryo to transfer (according to Gardners criteria)
patients that sign the accord to be enrolled in this study

Sponsors & Collaborators

Calla IVF Center
Otherlead

Study Sites (1)

Calla Ivf Center

Oradea, Bihior, 410103, Romania

Enrollment

65 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 12, 2024

First Posted

February 16, 2024

Study Start

January 1, 2022

Actual (reported)

Effect of Immunomodulatory Treatment on IVF (in Vitro Fertilization) Outcomes in Patients With KIR AA Genotype

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

KIR AA

KIR BX

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

KIR AA

KIR BX

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations